DTB: Vol 29, No 2

Content tools

Share it

Risks and uncertainties about gabapentinoids

Bol Inf Farmacoter Navar. 2021;29(2):1-14
https://doi.org/10.54095/BITN20212902EN

Descargar pdf

Off-label use of gabapentinoids is not recommended due to the lack of consistent evidence available and its potential risks (sedation, dizziness or respiratory depression). Some recommendations are provided for a safe prescription of gabapentinoids

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *

Authors:

- Natalia Alzueta. Medicines Advice and Information Service. Navarre Health Service

- Patricia García. Medicines Advice and Information Service. Navarre Health Service

-Irati Irigoyen. Servicio de Farmacia. Pharmacy Service of Complejo Hospitalario de Navarra. Navarre Health Service

navarra.es

DTB: Vol 29, No 2

Risks and uncertainties about gabapentinoids